# National Socioeconomic Disparities in Oncologic Resection for Small Cell Lung Cancer

Olisemeka Oputa, BA<sup>1\*</sup>; Krishay Sridalla, BA<sup>1\*</sup>; Kelly R. Bates, BA<sup>1</sup>; Ryan C. Jacobs, MD, MS<sup>1</sup>; Thomas Alexander, BA<sup>1</sup>; Rahul Burra, BA<sup>1</sup>; Dominic J. Vitello, MD, MS<sup>1</sup>; David J. Bentrem, MD, MS<sup>1,2</sup>

Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, <sup>2</sup>Department of Surgery, Jesse Brown Veterans Administration Medical Center, Chicago, Illinois

# Background

Small cell lung cancer (SCLC) is a rare but aggressive malignancy. Surgery is an essential component of treatment for patients with early-stage SCLC. This study examined socioeconomic disparities in utilization and outcomes for SCLC.

# Research Objectives

Assess racial disparities in the receipt of oncologic resection for patients diagnosed with SCLC and quantify the survival benefit associated with oncologic resection in patients with SCLC and explore potential barriers to surgical treatment among Black patients with SCLC.

## Methods

The National Cancer Database (NCDB) SCLC participant use file (PUF) was used to identify patients with T1/T2, N0, M0 (clinical stage I-IIA) SCLC diagnosed between 2004 and 2017. Multivariable logistic regression identified predictors of oncologic resection, while Cox regression assessed overall survival (OS):

## **Cohort Formation (NCDB 2004–2017)**

Total SCLC cases: 356,960

- → Exclude Stage IV or unknown stage: –267,310
- $\rightarrow$  Exclude non-T1/T2: -41,176
- $\rightarrow$  Exclude non-N0: -32,828
- → Exclude unknown M status: -1,658
- → Exclude unknown surgery status: –265
- → Exclude no diagnostic confirmation: −704

#### Final analytic cohort:

**12,946 patients** with T1/T2, N0, M0 SCLC, known metastatic & surgery status, and diagnostic confirmation

# Results

Black patients had significantly lower odds of receiving oncologic resection compared to White patients (aOR 0.71, 95% CI: 0.58–0.87; Figure 1)

Despite this disparity, Black patients demonstrated longer overall survival than White patients (aHR 0.88, 95% CI: 0.80–0.96; Figure 2).

Figure 1: Predictors of receiving oncologic resection





Figure 2: Predictors associated with overall survival

Covariate	aHR	95% CI							
Age	1.03	1.02 - 1.03			-				
Sex: Male (Ref)					1				
Sex: Female	0.87	0.83 - 0.91		<b>→■</b> •	 				
Race: White (Ref)					1				
Race: Black	0.88	0.80 - 0.96		6 × 🕮 × 1	!				
Race: Hispanic	0.84	0.71 - 1.00			1				
Race: Asian	0.93	0.73 - 1.17							
Race: Other	1.16	0.86 - 1.56							
Charlson Deyo Score: None (Ref)					!				
Charlson Deyo Score: Mild	1.08	1.02 - 1.13			F				
Charlson Deyo Score: Moderate	1.18	1.10 - 1.26			F - 10 - 4				
Charlson Deyo Score: Severe	1.4	1.27 - 1.54				-1			
Clinical Stage: Stage 1 (Ref)					!				
Clinical Stage: Stage 2	1.09	1.01 - 1.19			P				
Clinical Stage: Stage 3	2.21	1.62 - 3.01			:				•
Adjuvant Systemic Therapy Received: No (Ref)					!				
Adjuvant Systemic Therapy Received: Yes (Ref)	0.7	0.66 - 0.76		<b>&gt;</b> ■-1					
Insurance: Not Insured (Ref)									
Insurance: Private Insurance / Managed Care	0.96	0.80 - 1.16			H4				
Insurance: Medicare/Medicaid	1.06	0.88 - 1.28		***					
Income: <\$46,277 (Ref)					į				
Income: \$46,277 - \$57,856	0.91	0.86 - 0.98			i				
Income: \$57,857 - \$74,062	0.87	0.81 - 0.93		<b>&gt;</b> 4	į				
Income: \$74,063+	0.83	0.78 - 0.89		• 🖷 •	į				
Facility Type: Academic (Ref)					į				
Facility Type: Non-Academic	1.09	1.04 - 1.15							
Oncologic Resection Performed: No (Ref)					į				
Oncologic Resection Performed: Yes	0.6	0.55 - 0.64		<b>→ ■</b> +					
			Γ						
			0			.5	2	2.5	3
				Adjus	sted Hazar	d Ratio (9	5% CI)		

Figure 3: Kaplan-Meier survival estimates by Resection



### Limitations

Unmeasured confounders (e.g., smoking status) may influence results.

The NCDB captures data only from participating hospitals, which may not be representative of the broader U.S population.

Marginalized groups may be underrepresented potentially underestimating true disparities.

## Conclusion

Despite national guidelines, this study showed that oncologic resection is underutilized in Black patients even though it is associated with a survival benefit, highlighting its potential to improve outcomes if more widely adopted. Addressing these disparities through targeted interventions is essential to ensuring equitable access to guideline-concordant care. Future studies may perform qualitative analyses of surgical consultations for Black patients with SCLC to better understand reasons for underutilization.

## References

1.Janssen-Heijnen ML, Karim-Kos HE, van der Drift MA, et al. Modest improvements of survival for patients with small cell lung cancer aged 45 to 59 years only, diagnosed in the Netherlands, 1989 to 2008. *J Thorac Oncol*. Jan 2012;7(1):227-32. doi:10.1097/JTO.0b013e3182370e4c

2.Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest.* May 2013;143(5 Suppl):e400S-e419S. doi:10.1378/chest.12-2363